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Key Words: carcinoembryonic antigen, T-cell-bispecific antibody, minimum anticipated biological effect level, cancer immunotherapy, FIH dose selection, preclinical development (J Immunother 2016;00:000-000) C arcinoembryonic antigen (CEA), also known as carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), is a glycosylphosphatidylinositol-anchored cell-surface glycoprotein that plays an important role in cell adhesion, invasion, and metastasis of cancer cells. 1 Its expression in tumors is generally very high, especially in colorectal carcinoma, pancreatic cancer, gastric cancer, non-small cell lung cancer, and breast cancer. 2 CEA inhibits a process known as anoikis, whereby cells deprived of their anchorage to the extracellular matrix subsequently undergo apoptosis. Because of the polarized expression pattern and the luminal localization of CEA, its accessibility to therapeutic antibodies in normal tissues is considered to be low. A novel T-cell-bispecific (TCB) antibody has been developed, called CEA TCB, 3 which binds to human CEA (hCEA) and to the CD3 epsilon (CD3e) subunit of the T-cell receptor. Through the binding of the tumor antigen and CD3e on the T cell, an immunologic synapse is formed, resulting in cytokine, chemokine, and granzyme B release, followed by the activation and the proliferation of T cells. It is through this mechanism of action that the bispecific antibody exerts its activity on tumor cells, leading to tumor cell lysis. The in vitro and in vivo pharmacology of CEA TCB demonstrates its potent bispecific effect in lysing tumor cells. 3 As a result of targeting of a membrane-proximal domain of hCEA, CEA TCB displays preferential binding to membrane-anchored CEA rather than to shed CEA (sCEA), and the binding to CEA-expressing cells is not affected up to a concentration of 5 mg/mL of sCEA. 3 Specific regulatory requirements for preclinical safety evaluation of new biotechnology-derived pharmaceuticals are described in International Council on Harmonization (ICH) guidance documents (ICH Guidelines S6(R1), S9, M3(R2)). [4] [5] [6] These ICH agreements clarify, in general, that adequate safety studies need to be conducted in relevant animal species (ie, those in which the test material is pharmacologically active due to the expression of the desired epitope) to identify an initial safe dose and subsequent dose escalation schemes in humans.
The CEA antibody included in CEA TCB specifically binds to hCEA and does not cross-react with cynomolgus monkey CEA (cyCEA) consistent with the low amino acid sequence identity of 79%. Furthermore, CEA is not expressed in other animal models used for safety assessments including rodents due to the absence of true human orthologs. 7 Moreover, CEA TCB binds to CD3e both in humans and in cynomolgus monkeys, but does not crossreact with mouse CD3e. 3 Therefore, there are few animal models that can be used for the nonclinical safety assessment of CEA TCB.
Alternative nonclinical safety evaluation approaches, as described in the ICH S6 Guideline, 4 have been developed and assessed. These include a cynomolgus monkey crossreactive homologous (surrogate) antibody (cyCEA TCB) and its evaluation in cynomolgus monkey and the development of a double-transgenic mouse model expressing hCEA and human CD3e (hCEA/hCD3e Tg) and its evaluation with hCEA TCB.
When estimating the starting dose for human clinical trials, the no-observed-adverse-effect level (NOAEL) is generally used. NOAEL is determined from nonclinical safety studies conducted in the most sensitive and relevant animal species with appropriate allometric scaling and the addition of safety factors. The use of NOAEL depends on the existence of a relevant preclinical model or the development of an appropriate surrogate molecule model. When such models are not available, NOAEL cannot be used, and the minimum anticipated biological effect level (MABEL) approach may be used to determine the starting dose. The MABEL approach was introduced after the development of severe adverse events in the first human trial with the anti-CD28 super agonist monoclonal antibody (mAb; TGN1412), developed by TeGenero Immuno Therapeutics. 8 Since this occurrence, regulatory agencies have published guidelines for safer strategies to determine first-in-human (FIH) dosing, 9,10 and scientists have published on the application of a MABEL approach for FIH dose estimates. 11 The current article describes the preclinical approach implemented for determining the appropriate CEA TCB starting dose to be tested clinically. This approach involved the evaluation of the appropriateness of the preclinical in vivo models and the use of an in vitro MABEL approach for determining the starting dose on the basis of the most sensitive in vitro pharmacologically relevant assay. The starting dose is put in context of the pharmacologically active dose from in vivo and in vitro results, as well as the theoretical receptor occupancy.
MATERIALS AND METHODS

CEA TCB Binding
CEA TCB binding curves were developed in a range of in vitro cell models, including cynomolgus monkey peripheral blood mononuclear cells (PBMCs), Jurkat suspension cells, and A549 cells (see Supplementary Methods, Supplemental Digital Content 1, http://links.lww.com/JIT/ A440 for a description of how these cells were harvested and prepared). After cell preparation, 100 mL of the cell suspension (containing 0.2 Â10 6 cells) were incubated in a round-bottom 96-well plate for 30 minutes at 41C with increasing concentrations of the CEA TCB and respective cyCEA TCB (30 pM-500 nM), washed twice with cold phosphate-buffered saline (PBS) 0.1% bovine serum albumin (BSA), reincubated for further 30 minutes at 41C with the fluorescein isothiocyanate-conjugated AffiniPure F(ab 0 )2 Fragment goat anti-human immunoglobulin G (IgG) Fcg Fragment-Specific secondary antibody (Jackson ImmunoResearch Labs, West Grove, PA; Cat. No. 109-096-008), washed twice with cold PBS 0.1% BSA, and analyzed immediately by flow cytometry using a fluorescence-activated cell-sorting (FACS) Fortessa. Data were analyzed using the FACSDiva software (BD Biosciences, San Jose, CA), and binding curves and EC 50 values were obtained and calculated using Prism 5 software (GraphPad Software Inc., La Jolla, CA).
The Transgenic In Vivo Model
CEA is absent in rodents, and CEA TCB does not cross-react with mouse CD3e. Therefore, hCEA/hCD3e Tg double-transgenic mice expressing human CEA (CEA-CAM5) and human CD3e were generated in house by crossing hCEA Tg C57BL/6J-TgN(CE4Ge)18FJP mice 12 with hCD3e Tg mice.
Ex Vivo Evaluation of the Functional Activity of hCEA/hCD3e Tg Splenocytes
The functional activity of splenocytes from hCEA/hCD3e Tg mice was investigated ex vivo in tumor lysis experiments by incubation with Panc02-hCEA target cells (a murine pancreatic adenocarcinoma cell line overexpressing hCEA) and CEA TCB (E:T 50:1). Tumor lysis was detected after 48 hours by quantification of lactate dehydrogenase (LDH) release. The activity of hCEA/ hCD3e Tg splenocytes was compared with human PBMCs incubated with CEA TCB and the same target cells for 48 hours (E:T 10:1).
The half maximal effective concentration (EC 50 ) values were generated from the tumor cell lysis assay using Tg splenocytes and human PBMCs.
Immunohistochemistry (IHC) and Nanofluidic Quantitative Polymerase Chain Reaction (qPCR) hCEA protein expression was analyzed in fresh-frozen tissues from hCEA/hCD3e Tg mice. A total of 43 organs and tissues from hCEA/hCD3e Tg mice were collected, embedded in an optimal cutting temperature compound and fresh frozen. Cryostatic sections were analyzed by IHC staining using an anti-human CEA IgG antibody (T84.66 cloned with rabbit Fc, Roche Innovation Center, Zurich, Switzerland). Rabbit IgG Clone SP137 (Abcam, Cambridge, UK; Reference ab125938) was used as the isotype control on serial sections. The antibody against CEA was used at the concentration of 0.472 mg/mL on the Ventana Benchmark XT slide stainer with the DAB detection kit Map Ki (Ventana Medical Systems, Tucson, AZ). IHC-stained tissue sections were analyzed semiquantitatively for hCEA staining. The total CEA expression (staining intensity) and localization (cytoplasmic, nuclear, membranous) were evaluated.
Tissue mRNA expression analysis was performed on a subset of 11 tissues (brain, cerebellum, colon, esophagus, heart, kidney, liver, lung, spleen, stomach, and trachea) from hCEA/hCD3e Tg mice or on commercially available human specimens (Ambion; Thermo Fisher Scientific, Walthem, MA) using nanofluidic qPCR on a Fluidigm (South San Francisco, CA) 96 Â96 dynamic array and the BioMark system. Total RNA was isolated either from RNA-Later (Ambion) preserved tissue or from 10 6 cells from the LS174T-RFP cell line using the RNeasy Kit with DNaseI digestion on a solid support (Qiagen, Hilden, Germany). An aliquot (350 ng) of total RNA was reverse transcribed in 20 mL with anchored oligo-dT primer using the Roche Transcriptor kit. After cDNA synthesis, a 14-cycle multiplex PCR reaction (951C for 15 s, 601C for 4 min) was performed for preamplification using 2.5 mL of 1:10 diluted cDNA, 2.5 mL of 0.2 mM pooled forward and reverse primer mix, and 5 mL of 2Â TaqMan PreAmp Master Mix (Life Technologies, Thermo Fisher Scientific; PN 4391128). The preamplification product was diluted 1:5 in 1 Â TE buffer and then loaded with 2 Â TaqMan Universal PCR Master Mix (Life Technologies, PN 4304437), 20 mM forward and reverse primer, and 10 mM FAM labeled hydrolysis probe on a Fluidigm 96 Â96 dynamic array. The Fluidigm temperature program consisted of a 2 minutes' warm-up at 501C, preincubation at 951C for 10 minutes, followed by 40 cycles of amplification (951C for 15 s, 701C for 5 s, 601C for 60 s). Roche RealTime ready, Universal ProbeLibrary-based hydrolysis probe assays were used for the detection of human CEACAM5 (assay ID 115080), human TBP (assay ID 101145), human GAPDH (assay ID 102054), mouse Tbp (assay ID 300314), and mouse GAPDH (assay ID 307884). Real-time PCR data were analyzed using the Fluidigm Biomark software version 3.0.2. Measurements of cycle threshold values were performed for each sample qPCR-assay combination with 6 technical replicates. Expression levels of mRNAs present in a fixed amount of cDNA coming from 4.5 ng of total RNA were estimated according to the global standard curve method of Barber et al. 13 In Vitro Assay Selection
To implement an in vitro MABEL approach, EC 50 values were determined for several in vitro assays used to evaluate the pharmacological activity of CEA TCB (ie, tumor cell lysis, T-cell activation, T-cell proliferation, and cytokine release) and the most sensitive assay and tumor lines chosen.
Tumor Cell Lysis Mediated by CEA TCB
Non-transfected A549 cells and A549 cells transfected to express hCEA (hCEA-A549) or cyCEA (cyCEA-A549) were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, 1% glutamine, and 4 mg/mL puromycin (transfected cells only). The day before performing the tumor cell lysis assays, target cells were harvested with 0.05% trypsin/ethylenediaminetetraacetic acid (Life Technologies; Cat. No. 25300-096), washed in PBS, and seeded at 25,000 cells per well in 96-well flatbottom plates. Cells were incubated overnight at 371C and 5% carbon dioxide (CO 2 ). Human or cynomolgus monkey PBMCs were used as effector cells. Human PBMCs were prepared by Histopaque-1077 density centrifugation of enriched lymphocyte preparations (buffy coats) obtained from healthy donors. Fresh blood from cynomolgus monkeys was diluted with sterile PBS and layered over Histopaque-1077 gradient (Sigma-Aldrich, Saint Louis, MO; Cat. No. H8889). After centrifugation (450g, 30 min, room temperature), the plasma above the PBMC-containing interface was discarded, and PBMCs were transferred to a new falcon tube subsequently filled with 50 mL of PBS. The mixture was centrifuged (400g, 10 min, room temperature), the supernatant discarded, and the PBMC pellet washed twice with sterile PBS (centrifugation steps 350g, 10 min). The resulting PBMC population was counted automatically (ViCell; Beckman Coulter, Pasadena, CA) and stored in Rosewell Park Memorial Institute 1640 medium containing 10% fetal bovine serum and 1% L-alanyl-L-glutamine (Biochrom, K0302) at 371C and 5% CO 2 in a cell incubator until assay start. For the tumor lysis assays, PBMCs were added to target cells (hCEA-A549, cyCEA-A549, A549) at a final E:T ratio of 10:1 together with CEA TCB or cyCEA TCB at a concentration range of 6 pM-100 nM. All samples were tested in triplicate. Target cell killing (tumor cell lysis) was assessed after 24 hours of incubation at 371C and 5% CO 2 by quantification of the LDH released into cell supernatants by apoptotic/necrotic cells (LDH detection kit; Roche, Cat. No. 11 644 793 001). Maximal lysis of the target cells (100%) was achieved by the incubation of target cells with 1% Triton X-100. Minimal lysis (0%) refers to target cells coincubated with effector cells without a bispecific construct.
T-Cell Activation and Proliferation in Whole Blood
Venous blood from healthy blood donors (Roche Infirmary Services, Basel, Switzerland) or cynomolgus monkeys (Roche Animal Husbandry, Basel, Switzerland) was collected in vacutainer tubes with lithium heparin as the anticoagulant and kept at room temperature until initiation of the assay, which was within 3 hours of blood withdrawal. For each assay, 195 mL of whole blood was added to test items (5 mL volume, in triplicate) in 96-well round-bottom plates, followed by incubation at 371C with 5% CO 2 for 24 hours. Cells and plasma were separated by centrifugation at 1800g for 5 minutes, and plasma samples (70 mL volume) were stored at À 801C until analysis of the cytokine content.
For flow cytometric analysis of T-cell antigen upregulation, 50 mL of cynomolgus monkey cells and human cells were stained with a range of antibodies (Supplementary Table 1 , Supplemental Digital Content 2, http:// links.lww.com/JIT/A441) for 30 minutes at room temperature. After washing, erythrocytes were lysed with BD Pharm Lyse buffer (BD Biosciences; Cat. No. 555899, whole blood samples only). Cells were then washed and resuspended. Samples were acquired on a BD Canto II flow cytometer and analyzed using FlowJo software (Tree Star).
Cytokine Release in Whole Blood
Using the same venous blood samples as described previously, human plasma samples were diluted 1-4, and analyte concentrations were determined by an enzymelinked immunosorbent assay using the human cytokine chemiluminescent assay kit (Aushon SearchLight, Cat. No. 84619B; Aushon Biosystems, Billerica, MA) with the SignaturePLUS imaging system and the PROarray analysis software. The reconstitution volume of interleukin (IL)-6, IL-8, and tumor necrosis factor-a (TNFa) standards was adapted to extend the standard curve up to 2000, 8000, and 1920 pg/mL, respectively. For the measurement of cytokines in cynomolgus plasma, non-human primate cytokine chemiluminescent assay kits were used (Aushon SearchLight, Cat. No. 870408 [5-plex] and 870429 [1-plex] ). Plasma samples were diluted 1-4 for the 5-plex and 1-2 for the 1-plex assay. Data are presented as the mean of cytokine measurements in supernatants from triplicate wells. Results are expressed as pg/mL.
Dose Selection Based on an In Vitro MABEL Approach
Of the in vitro assays tested, the tumor lysis assay proved to be the most sensitive assay (see the Results section), and the 2 most sensitive tumor cell lines were used to determine the mean 20% maximal effective concentration (EC 20 ) of tumor cell lysis by PBMCs isolated from 30 donors. These cell lines were the MNK45 gastric tumor cell line and the A549-hCEA cell line. MNK45 is a gastric carcinoma line, which expresses very high, but variable, levels of CEA endogenously, ranging from 280,000 to 570,000 CEA binding sites/cell, depending on cell confluence (internal data). A549-hCEA is a stable clone derived from an A549 lung adenocarcinoma cell line, which was transfected with the plasmid coding for hCEA. The A549-hCEA cell line displays more stable CEA expression, which is insensitive to cell confluence (230,000 CEA binding sites/ cell, internal data).
By relating the EC 20 value to the predicted maximum plasma concentration (C max ) in humans, the starting dose can be determined by basing the plasma volume on a generic value of 3 L. 14 The relationship of the FIH starting dose was then compared with the in vivo efficacious dose and the expected receptor occupancy.
The In Vivo Efficacious Dose
An efficacy model was developed using human PBMCs transferred into tumor-bearing NOG mice at different E:T ratios. In this model, an efficacious dose associated with tumor regression was 2.5 mg/kg. 3 Using the average concentration at a steady state (C ave,ss ) of this dose from immunocompetent C57BL/6 mice, a human equivalent efficacious dose was calculated from the following equation, using generic clearance values for IgGs in humans:
where CL hu is the predicted human clearance, C eff,ss the predicted efficacious concentration, and Tau the dosing interval, respectively.
The generic clearance for humans was taken as 0.2 mL/h/kg. 15 Clearance was faster than expected in both mice and cynomolgus monkeys by at least 2-fold (data not shown). Therefore, a factor of 2 was applied to the clearance to align with the faster clearance observed in the monkey study, because this may also be the case in humans during both CD3 binding and immune cell activation. The C eff,ss was assumed to be equal to the C ave,ss taken from the 2.5 mg/kg dose in C57BL/6 mice (6 mg/mL), and a Tau of 1 week (168 h) was used.
Theoretical Receptor Occupancy
Theoretical receptor occupancy-based considerations constitute another approach to derive MABEL-based starting doses. Either the occupancy at a given efficacious concentration (eg, EC 20 ) is calculated or concentrations yielding a predefined low receptor occupancy are determined. Because this is a bispecific antibody that requires simultaneous engagement of 2 receptors expressed on 2 different cell types for efficacy (ie, CEA on tumor cells and CD3 on T cells), it is not possible to calculate the actual receptor occupancy of both receptors at the same time. Therefore, a theoretical receptor-occupancy approach was used to calculate the binding to the CD3e receptor and the CEA receptor separately, as a bifractional approach.
Two theoretical approaches can be applied. One is based on the Michaelis-Menten equilibrium equation (Method 1), assuming that the amount of mAb is much higher than the amount of target. The second approach (Method 2) takes into account higher target concentrations. 16 Method 1 (the Michaelis-Menten approach):
K d is the dissociation constant (80 nM for CD3e and 0.2 nM for CEA); [mAb] is the concentration of mAb. Method 2:
RO is the receptor occupancy; K d is the dissociation constant; TD is the total drug concentration (taken as EC 20 from tumor lysis assay); TT is the total target concentration. The total target concentration (TT) was calculated as follows:
where TT is the total target concentration, n 1 is the number of CD3e receptors per cell (6.11 Â10 4 ), 17 n 2 is the number of T cells per volume (1.3Â 10 9 L À 1 ), 16 and N A is the Avogadro constant.
RESULTS
Binding of CEA TCBs to CD3-expressing and CEAexpressing Cells
To assess the cynomolgus monkey cross-reactive homologous (surrogate) antibody, cyCEA TCB, its binding to a set of antigen-expressing cells was determined. hCEA TCB and cyCEA TCB displayed comparable binding to hCD3e-expressing Jurkat cells (Fig. 1A) . The binding curves did not reach saturation, owing to the monovalent and low-affinity binding to hCD3e and cyCD3e (100 nM, surface plasmon resonance measurements). When tested on cyCD3e-expressing cells (freshly isolated cynomolgus PBMCs), cyCEA TCB showed weaker binding than CEA TCB at higher antibody concentrations (Fig. 1B) . This finding was unexpected given that both constructs contain the same CD3e binder and were comparable in their binding to Jurkat cells. 
cyCEA TCB-induced Tumor Cell Lysis
Tumor lysis assays were performed with cyCEA TCB and CEA TCB. Both molecules were comparable in inducing CEA-specific tumor lysis of their respective target cells when incubated with human PBMCs as effector cells (Fig. 2B) . Neither molecule induced tumor cell lysis in A549 cells expressing low levels of endogenous hCEA.
The specificity of killing was further investigated by using cynomolgus monkey PBMCs as effector cells. As expected, cyCEA TCB led to the killing of A549-cyCEA cells ( Fig. 2A, left) and CEA TCB led to target-specific killing of A549-hCEA cells ( Fig. 2A, right) . Unexpectedly, cyCEA TCB also induced the killing of both hCEA-A549 and A549 cells ( Fig. 2A, left) even though neither express the cyCEA target. CEA TCB did not induce the killing of cyCEA-A549 or A549 cells ( Fig. 2A, right) .
cyCEA TCB-induced T-Cell Activation in Whole Blood
Experiments in cynomolgus monkey whole blood showed that although cyCEA TCB induced the upregulation of the activation marker CD69 on T cells and natural killer (NK) cells in the absence of a target (Fig. 3A) , CEA TCB did not induce the activation of T cells and NK cells in cynomolgus monkey or human whole blood (Figs. 3A and  B, respectively) .
In addition, incubation of whole blood with cyCEA TCB for 24 hours induced the cytokines IL-6, IL-8, TNFa, and interferon-g in cynomolgus monkey whole blood, whereas incubation with CEA TCB did not ( Supplementary  Fig. 1 , Supplemental Digital Content 3, http://links.lww.com/ JIT/A442).
As both the activation marker and cytokine assays showed different patterns with cyCEA TCB and CEA TCB, these data demonstrate that cyCEA TCB is not representative of CEA TCB. The use of cyCEA TCB in vivo would potentially result in irrelevant toxicities in cynomolgus monkeys, which would be difficult to interpret and would misrepresent the effects of CEA TCB in humans. Therefore, the surrogate homolog, cyCEA TCB, could not be used in nonclinical safety studies.
The Characterization of hCEA/hCD3e Tg Mice
EC 50 values generated from the tumor cell lysis assay using hCEA/hCD3e Tg splenocytes and human PBMCs are shown in Table 1 . These data show that hCEA/hCD3e Tg splenocytes display an approximately 40-fold lower potency than human PBMCs evaluated in parallel. Moreover, the lower potency of hCEA/hCD3e Tg splenocytes is also demonstrated by the higher E:T ratios (50:1 for splenocytes vs. 10:1 for human PBMCs) required for tumor killing.
In summary, the ex vivo functional characterization of the activity of hCEA/hCD3e Tg splenocytes demonstrated that these cells are able to induce tumor cell killing, but display an approximately 40-to 50-fold lower potency than human PBMCs.
The Evaluation of hCEA Expression in hCEA/hCD3e Tg Mice CEA expression was present sporadically in the colon of hCEA/hCD3e Tg mice, with occasional epithelial glandular cells in the crypts showing strong membranous and cytoplasmic staining (Fig. 4) . Only weak staining was noted in scattered epithelial cells in the stomach and the cecum and in the cerebellum. No CEA expression was found by IHC in any of the other tissues evaluated from transgenic mice.
Human CEA mRNA was expressed in the colon, the stomach, and the trachea in both hCEA/hCD3e Tg mice and human tissues (Fig. 5) . In addition, CEA mRNA signals were detected in the lung of hCEA/hCD3e Tg mice at very low expression levels, much lower than the signals in lung tissue from a human donor. In contrast to human tissues, CEA mRNA was also expressed in the brain and the cerebellum of hCEA/hCD3e Tg mice.
Therefore, on the basis of ex vivo analyses, the hCEA/ hCD3e Tg mice were determined to be unsuitable for the safety assessment of CEA TCB, because both the functional activity (potency) of splenocytes and the expression of CEA do not fully represent the human system.
Dose Selection Based on an In Vitro MABEL Approach
Because of the low functional activity of splenocytes from hCEA/hCD3e Tg mice and the differences in the distribution of human CEA in tissues of hCEA/hCD3e Tg mice compared with human tissues, the hCEA/hCD3e Tg mice were determined to be not relevant for the safety assessment of CEA TCB. Because of the lack of an appropriate toxicological nonclinical model, it was not possible to estimate the NOAEL. Thus, an in vitro MABEL approach was implemented for the determination of the FIH starting dose.
Out of all the in vitro assays conducted, the most sensitive was the tumor cell lysis assay, which was at least 4-to 5-fold more sensitive than other pharmacological readouts (Fig. 6) .
The tumor cell lysis assay involves the engagement of both the CEA receptor and the CD3e co-receptor of the Tcell receptor to induce tumor cell lysis, which makes it directly relevant to the mechanism of action of CEA TCB. The 2 most sensitive tumor cell lines, MKN45 and A549-hCEA, were used to determine the mean EC 20 of tumor cell lysis by PBMCs isolated from 30 donors. The mean EC 20 value was 46.7 ng/mL (242 pM) for the MKN45 cell line and 17.2 ng/mL (89 pM) for the A549-hCEA cell line (data not shown).
On the basis of the EC 20 of the in vitro models and a 3 L plasma volume in humans, the suggested starting dose was calculated to be 52 mg (0.736 mg/kg for a 70 kg person) for the A549-hCEA tumor cell lines and 140 mg (2.00 mg/kg for a 70 kg person) for the MNK45 tumor cell lines. The lower dose of 52 mg was chosen as the starting dose on the basis of the in vitro MABEL approach from the tumor cell lysis assay, providing the most conservative starting dose.
The In Vivo Efficacious Dose
On the basis of previous data showing that an efficacious dose associated with tumor regression was 2.5 mg/kg, 3 a pharmacologically active in vivo dose of 403 mg/kg was derived.
Theoretical Receptor Occupancy
Both Method 1 and Method 2 used to calculate receptor occupancy (see the Materials and methods section) yielded similar results for CD3e, with a value of 0.11% CD3e receptor occupancy for a dose based on the EC 20 of the tumor cell lysis assay (A549-hCEA cell line). This is well below the 1% receptor occupancy often suggested for receptor agonists. 18 For 1% receptor occupancy of CD3e, the dose would be 6.7 mg/kg. For the CEA receptor, the EC 20 -based dose corresponded to a receptor occupancy of about 31% on the basis of Method 1. Thus, 31% of the CEA receptors would be occupied at the corresponding receptor occupancy of 0.11% for CD3e receptors. Because of the lack of information on tumor cell density for CEAexpressing tumors, Method 2 was not implemented. Receptor occupancy at each of the theoretical in vivo doses is illustrated in Figure 7 .
DISCUSSION
Syntenic mapping of genomes across multiple species showed that a human ortholog of CEA (or CEACAM5) is present in macaques such as rhesus and cynomolgus monkeys, but absent in dogs or rodents. 7 As CEA TCB is not cross-reactive in cynomolgus monkeys, preclinical toxicological studies for CEA TCB have not been performed due to the lack of a relevant species. Therefore, 2 separate approaches were undertaken: a comparison of a cynomolgus monkey surrogate molecule (cyCEA TCB) with the CEA TCB clinical lead, and the generation and the characterization of a double-transgenic mouse model for human CEA and human CD3e. The cyCEA TCB surrogate molecule induced the in vitro non-specific killing of cells and the non-specific activation of T and NK cells. The hCEA/hCD3 Tg double-transgenic mice were considered as not relevant, because the functional activity of T cells in this animal model was approximately 40-to 50-fold lower than that of human PBMCs, and the CEA tissue expression In particular, membranous staining is present in the upper layer of the squamous epithelium in the esophagus and the tongue and in the glandular epithelial surface of the stomach, the small intestine, and the large intestine. 19 Intense staining in the bronchial and the alveolar epithelium and in the secretory epithelia of sweat glands has been also reported. 20 The tissue protein expression of CEA, assessed with specific antibodies, and the mRNA profile in hCEA/hCD3e Tg mice and human tissues suggests a substantially different expression pattern, with mice showing a low intensity and a low frequency of staining and variable distribution compared with humans.
A human PBMC transfer to a xenograft mouse model was used to explore the pharmacology of CEA TCB's mechanism of action. 3 The in vivo pharmacology model proved the concept of bispecific activity, but was not a viable representative model of the human situation, for example, due to the systemic absence of human CEA orthologs in mouse and the finding that CEA TCBs do not cross-react with mouse CD3e. Thus, no toxicological model was available for determining the NOAEL, and an in vitro MABEL approach was implemented to calculate a safe starting dose for human testing.
Surrogate molecule approaches are requested by regulatory agencies 9, 10 to explore relevant alternatives to a lack in cross-reactivity to other species and have been implemented. 21 Although these approaches may be explored in preclinical programs, there are many drawbacks. Proving the similarity between the surrogate molecule and the clinical lead involves significant bioengineering investment, molecule characterization, and functional activity assessment. These approaches have a high risk of failing, especially in the field of immunomodulators. Many humanized mouse models are being developed to fill the gap in preclinical models, 22 which would circumvent the necessity of using surrogate molecules, but these also have their challenges.
It is not clear as to why there was insufficient T-cell functional activity in the hCEA/hCD3e transgenic mice. Protein expression in transgenic mouse models that is representative of the human expression patterns is often a concern and requires rigorous characterization. Unfortunately, this model demonstrated both insufficient T-cell functional activity and a CEA tissue distribution that was different when compared with human tissues, and therefore, could not be used for the safety assessment of CEA TCB. The relationship of exposure to the CEA TCB's mechanism of action was not known at the time of the dose calculations. Until the T-cell trafficking to the tumor and the degree of infiltration of the tumor are better understood, it will be difficult to determine the optimal dosing regimen. Here, we have used the C max for the starting dose calculation, implying that the immune response is induced by an initial peak concentration. This is, in part, because our most reliable data were obtained in vitro and a peak dose level will likely attain the necessary receptor occupancy required on the T cells and tumor cells to induce a bispecific response or tumor cell lysis. It can be argued equally that exposure over a certain amount of time may be a more important determinant of the optimal dose, because once minimal receptor occupancy is attained, no further CEA TCB binding is required for tumor cell lysis. Thus, excess levels of the molecule may not be necessary. In some preliminary in-house experiments, it appears that a minimum plasma concentration or a concentration threshold must be reached multiple times in a short period to obtain better efficacy. Such an effect could be explained through Tcell margination in and out of tissues and tumor, thus requiring a constant or well-timed exposure to the TCB at a minimum concentration level. The dosing regimen required for immunomodulators needs further exploration because it is unknown as to how well preclinical models translate to the clinical situation, where peripheral low-level expression of the tumor antigen may interfere with effects targeted at the tumor due to peripheral sinks or tissue binding, not to mention any potential nonspecific binding. The pharmacological effect of CEA TCB is dependent on the simultaneous binding to the tumor antigen (CEA) on a solid tumor and the CD3e subunit on intratumor T cells. No safety margins were incorporated for the starting dose because basing the dosing on the C max inherently incorporates safety factors, as it does not take into account the distribution of CEA TCB to the tumor through tissues, the transmigration of T cells with bound CEA TCB, or the time required for the recruitment of circulating T cells to the tumor area. The current understanding based on IHC analysis and the literature indicates that the levels of CEA are low and appear inaccessible in normal tissue. 19 Thus, a C max -based approach underestimates the efficacious dose, but provides a safe starting dose, especially when no exhaustive preclinical studies can be conducted.
On the basis of theoretical receptor occupancy, the estimated dose derived from the in vitro MABEL approach was clearly the lowest starting dose for FIH and was considered as the safest dose for starting clinical trials. This dose is >1000 times lower than the one that would induce significant levels of cytokine release (100 nM based on data from whole-blood assays). The estimated starting dose would have been >2 times higher if the EC 50 of the most sensitive assay was used for dose calculations rather than the EC 20 . Both doses are below the level required to achieve 1% CD3e receptor occupancy, suggested as the threshold at which agonistic molecules begin to induce immunomodulation. Although these doses are below the predicted estimated efficacy, the implementation of MABEL was used to ensure a safe starting dose.
In conclusion, these nonclinical safety studies support an FIH starting dose of 52 mg on the basis of a conservative in vitro MABEL approach. From this information, the only identified safety concern for the proposed clinical trial is the potential for infusion-related reactions. This potential risk is mitigated appropriately in the clinical protocol. %RO CEA FIGURE 7 . Dose calculations in relation to receptor occupancy. Theoretical % receptor occupancy was estimated for both CEA and CD3e receptors and compared with the corresponding flat human dose. The in vitro minimum anticipated biological effect dose, the EC 50 of the tumor cell lysis assay, the 1% receptor occupancy on the CD3e dose, and the in vivo-based doses are displayed in the figure ordered according to the flat human dose. These were much lower than the cytokine release cut-off from the whole-blood assay of 100 nM.
